Liao Li, Li Xiaoxuan, Xu Hong, Tang Jing, Li Bo, Tang Yan, Xie Fang
Pharmaceutical Department, The Second People's Hospital of Yibin-Yibin Hospital of West China Hospital of Sichuan University, Yibin, China.
Clinical Pharmacy Department, Third Affiliated Hospital of Chengdu Medical College-Chengdu Pidu District People's Hospital, Chengdu, China.
Front Pharmacol. 2025 Jun 3;16:1586265. doi: 10.3389/fphar.2025.1586265. eCollection 2025.
Coronary Heart Disease (CHD) stands as a predominant cardiovascular ailment globally, posing a severe menace to human health. Central to both hemostasis and the pathogenesis of coronary atherosclerotic thrombosis are platelets. In recent years, their significance has expanded beyond mere involvement in clot formation; they have been implicated in heightened immune responses, contributing to tissue inflammation (evident in myocardial ischemia) and vascular inflammation (crucial in vulnerable plaque formation). While contemporary antiplatelet therapies have markedly enhanced clinical outcomes for patients with coronary artery disease, they inadvertently escalate the hazard of bleeding complications. This review delves into the intricate mechanisms by which platelets influence the progression of coronary artery disease and meticulously examines the prospective utility of herbal antiplatelet interventions. Our objective is twofold: firstly, to furnish clinicians with scientifically grounded and valuable therapeutic alternatives for managing coronary artery disease, and secondly, to stimulate research and development endeavors aimed at creating novel, more efficacious antiplatelet medications that strike a balance between efficacy and safety.
冠心病（CHD）是全球主要的心血管疾病，对人类健康构成严重威胁。血小板是止血和冠状动脉粥样硬化血栓形成发病机制的核心。近年来，它们的重要性已不仅限于参与凝血；它们还与免疫反应增强有关，导致组织炎症（如心肌缺血中所见）和血管炎症（在易损斑块形成中至关重要）。虽然当代抗血小板疗法显著改善了冠心病患者的临床结局，但它们无意中增加了出血并发症的风险。本综述深入探讨血小板影响冠状动脉疾病进展的复杂机制，并仔细研究草药抗血小板干预措施的潜在效用。我们的目标有两个：一是为临床医生提供科学合理且有价值的治疗选择，用于管理冠状动脉疾病；二是激发研发努力，以创造新型、更有效的抗血小板药物，在疗效和安全性之间取得平衡。
